Navigation Links
Covance Launches Managed Markets Services

PRINCETON, N.J., Aug. 6, 2013 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, announced the creation of a new service offering focused on providing its biopharmaceutical and medical device clients support to effectively manage contracts in managed markets.  Steve Medina, Vice President, Managed Market Services, is leading this new effort.

Covance's managed markets services will help clients maximize value by improving controls and management of contract terms and associated payments.  The new service will also help biopharmaceutical and medical device clients obtain higher market share by gaining better visibility into contract performance with managed care organizations, group purchasing organizations, federal and state programs, and wholesalers.

The service targets a substantial need in the marketplace as chargebacks and rebates used in contracts account for as much as 20 percent of US gross sales for biopharmaceutical and medical device companies (approximately $50 billion a year).  Without the right controls and contracting processes in place, biopharmaceutical and medical device companies risk both revenue loss and potential penalties associated with a failure to comply with government regulations.  It is estimated that biopharmaceutical and medical device companies currently lose up to 4.4 percent of US revenue per year, or $11 billion a year, due to insufficient processes and contract management systems at a time when the economic environment for the sale of drugs and devices has never been more challenging.

"Covance is pleased to have invested in the expertise and technology to help biopharmaceutical and medical device clients prevent significant annual revenue losses from insufficient oversight of the contracts that are used to negotiate price and formulary placement with insurance companies, wholesalers and the government," said Marc Ginsky, Vice President and General Manager, Covance Market Access Services.  "These contracts have become increasingly complex over the past several years and the acquisition and maintenance of the talent and technical infrastructure required to set up, maintain, and manage contracts without revenue leakage is a significant struggle for our clients."

"Covance's managed markets services can transform a labor-intensive, time-consuming, and costly process into a far simpler and more efficient service platform for our clients," said Steve Medina, Vice President, Managed Markets Services.  "We believe that no other company currently offers a full-service, end-to-end solution across all types of contracts and services, with a full technical environment provided as part of the underlying service."

Covance's managed markets services will be led by Steve Medina, who joined Covance in July 2012.  Medina came to Covance from HighPoint Solutions, where he was Vice President, Managed Service.  Prior to this, Medina was the Practice Leader of the BTS Delivery Services Organization within IMS Health, the delivery services organization responsible for providing specialized solutions and on-going services to life sciences companies.  His career includes 23 years of consulting, focused on health care product manufacturing.  He specializes in ongoing service solutions, account management, and systems implementation.  Medina has extensive experience with contract management, as well as sales and marketing.

More information about Covance's managed markets services can be found at

About Covance Inc.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 12,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at

Forward-Looking Statements
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Financial Results, Earnings Schedules, Quarterly Dividends, and Top Rankings - Research Report on Quest Diagnostics, PerkinElmer, PAREXEL, Covance, and ICON
2. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2013 Financial Results Conference Call
3. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
4. Covance Central Laboratory Services Again Ranks #1 in Global Investigator Satisfaction Survey
5. Covance To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
6. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
7. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
8. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
9. Covance To Present At The Citi 2013 Global Healthcare Conference
10. Covance To Present At The Leerink Swann Global Healthcare Conference
11. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Post Your Comments:
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... WASHINGTON , Nov. 25, 2015  The ... Obstetricians and Gynecologists (ACOG), and the March of ... bipartisan Protecting Our Infants Act of 2015 ... the number of newborns born exposed to drugs, ... Since the bill,s introduction, all three organizations have ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
Breaking Medicine Technology:
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 , ... ... Thanksgiving through Christmas Eve on several models of traditional and far-infrared saunas. ... . Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and UN ... African Centres of Excellence, and public R&D institutions, civil societies and other partners ... the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The ...
Breaking Medicine News(10 mins):